$31.99
0.09 (+0.28%)
Bristol-Myers Squibb Co. (NYSE:BMY)
CAPS Rating:
Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments.
Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
Recs
The insiders are buying. The dividend is fat. They haven't eaten up another company like their bio/pharma bretheren (think PFE, MRK, Roche), so they don't have any rocky integrations to worry about. They have a stocked pipeline ( http://www.bms.com/research/pipeline/Pages/default.aspx).
Plus, we have a 1995 sale price. If you ever wanted to go back in time, well...